他汀类药物使用与膝骨关节炎结局指标:基于Heberden结节存在与否的骨关节炎倡议研究
基于骨关节炎倡议(OAI)队列的纵向1:1倾向评分匹配回顾性分析,按基线Heberden结节(HN)状态分层,评估他汀使用与影像学膝骨关节炎(Kellgren-Lawrence分级≥2)发生及关节间隙狭窄(JSN)进展的关系。HN阳性队列中他汀使用者JSN进展风险降低46%(HR 0.54;95%CI 0.36, 0.93;P=.02),HN阴性队列中他汀使用与JSN进展无关联(HR 1.37;95%CI 0.74, 2.53;P=.32)。
要点
- HN阳性膝骨关节炎患者中,他汀使用与JSN进展风险降低46%相关(HR 0.54;95%CI 0.36, 0.93;P=.02)。
- HN阴性队列中他汀使用与JSN进展无关联(HR 1.37;95%CI 0.74, 2.53;P=.32)。
- 按基线Heberden结节状态分层可能有助于识别他汀对膝骨关节炎影像学进展的潜在应答人群。
核心结论
- 他汀使用与结节性骨关节炎患者的影像学膝骨关节炎关节间隙狭窄进展风险降低相关。
研究设计与样本
- 骨关节炎倡议(OAI)队列(2004年开始并持续进行,ClinicalTrials.gov标识NCT00080171)的纵向1:1倾向评分匹配回顾性分析,采用符合方案和新使用者设计匹配他汀起始者(入组前报告他汀使用≤1年)与非使用者(入组前报告无他汀使用),每年随访共8年。HN阳性队列纳入602名参与者的832个膝关节(平均年龄64.7岁±8.0,女性377例[62.6%]);HN阴性队列纳入285名参与者的386个膝关节(平均年龄58.9岁±8.2,女性144例[50.5%])。
诊断标准与关键数值
- 影像学膝骨关节炎发生定义为Kellgren-Lawrence分级≥2;关节间隙狭窄进展和非可接受症状状态发生采用Cox回归风险比评估。HN阳性队列他汀使用者JSN进展HR 0.54(95%CI 0.36, 0.93;P=.02),HN阴性队列HR 1.37(95%CI 0.74, 2.53;P=.32)。
临床应用与阅片要点
- 阅片和报告时可关注基线Heberden结节状态,结合其分层评估他汀使用与膝骨关节炎JSN进展风险的关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The exact contribution of statins to knee osteoarthritis (OA) radiographic outcomes and the characteristics of patients with OA as potential responders to statins remain unclear. Purpose To evaluate the effect of statin use on the incidence of radiographic knee OA (development of Kellgren-Lawrence grade ≥2) and progression of joint space narrowing (JSN) according to the nodal OA status defined according to the presence of Heberden nodes (HNs). Materials and Methods Institutional review boards approved this HIPAA-compliant protocol, and all participants gave informed consent. The Osteoarthritis Initiative (OAI) cohort, which began in 2004 and is ongoing (https://clinicaltrials.gov identifier, NCT00080171), was used to conduct a longitudinal 1:1 propensity score-matched retrospective analysis of prospectively collected data. Participants were classified as having HN-positive or HN-negative findings according to the presence of HNs at baseline physical examination. In each cohort, per-protocol and new-user design were used to match statin initiators (participants who reported ≤1 year of statin use before enrollment) and nonusers (participants who reported no statin use before enrollment) for variables that potentially contributed to confounding by indication bias. Participants were followed up annually over 8 years. Any associations between statin use and longitudinal knee OA radiographic incidence, JSN progression, or nonacceptable symptomatic state incidence was assessed by using hazard ratios (HRs) of Cox regression. Results In the longitudinal analysis, there were 832 knees of 602 participants (pair-matched knees of statin initiators and nonusers) in the HN-positive cohort (mean age, 64.7 years ± 8.0 [standard deviation]; 377 patients were female [62.6%]) and 386 knees of 285 participants in the HN-negative cohort (mean age, 58.9 years ± 8.2; 144 patients were female [50.5%]). In the HN-positive cohort, statin users had 46% lower risk of JSN progression in comparison with matched nonusers (HR, 0.54; 95% confidence interval [CI]: 0.36, 0.93; P = .02). In contrast, in the HN-negative cohort, statin use had no association with radiographic JSN progression (HR, 1.37; [95% CI: 0.74, 2.53]; P = .32). Conclusion Statin use was associated with reduced risk of radiographic knee osteoarthritis joint space narrowing progression in patients with nodal osteoarthritis. © RSNA, 2019 Online supplemental material is available for this article.
引用
- Haj-Mirzaian A, Mohajer B, Guermazi A, et al. Statin Use and Knee Osteoarthritis Outcome Measures according to the Presence of Heberden Nodes: Results from the Osteoarthritis Initiative. Radiology. 2019. PMID: 31502936. doi:10.1148/radiol.2019190557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。